Page 14 - GALENIKA MEDICAL JOURNAL

Results: A total of 60 critically ill patients on hemodialysis were included in this study. Estimated vancomycin clearance and
volume of distribution values in the base model were 1.16 L/h and 324 L, respectively. The full PPK model of vancomycin
had 5 significant covariates: daily dose of vancomycin, weekly number of hemodialysis sessions, duration of each dialysis
session, co-administration of levofloxacin, and co-administration of fluconazole. It was shown that only 1 out of 5 individual
covariates from the full model met the necessary statistical requirements, and that was the daily dose of vancomycin.

Conclusion: Vancomycin clearance in hemodialysis patients depends on various factors, including dialysis efficiency and
patient characteristics. Clinicians must carefully monitor vancomycin levels in hemodialysis patients, adjusting doses as
needed to ensure therapeutic efficacy while minimizing the risk of toxicity.

Keywords: population pharmacokinetics, vancomycin, hemodialysis

Literatura 14. Lewis SJ, Nolin TD. New Vancomycin Dosing Guidelines for Hemodialysis
Patients: Rationale, Caveats, and Limitations. Kidney360. 2021 May
21;2(8):1313-5.
1. Wang F, Zhou H, Olademehin OP, Kim SJ, Tao P. Insights into Key 15. Cimino C, Burnett Y, Vyas N, Norris AH. Post-Dialysis Parenteral
Interactions between Vancomycin and Bacterial Cell Wall Structures. Antimicrobial Therapy in Patients Receiving Intermittent High-Flux
ACS Omega. 2018 Jan 31;3(1):37-45. Hemodialysis. Drugs. 2021 Apr;81(5):555-74.
2. Koulenti D, Xu E, Song A, Sum Mok IY, Karageorgopoulos DE, 16. Launay-Vacher V, Izzedine H, Mercadal L, Deray G. Clinical review: use of
Armaganidis A, et al. Emerging Treatment Options for Infections by vancomycin in haemodialysis patients. Crit Care. 2002 Aug;6(4):313-6.
Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms.
2020 Jan 30;8(2):191. 17. Pollard TA, Lampasona V, Akkerman S, Tom K, Hooks MA, Mullins RE, et
3. Patel S, Preuss CV, Bernice F. Vancomycin. In: StatPearls [Internet]. al. Vancomycin redistribution: dosing recommendations following high-
flux hemodialysis. Kidney Int. 1994 Jan;45(1):232-7.
Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Feb 17].
Available online: http://www.ncbi.nlm.nih.gov/books/NBK459263/ 18. Mulubwa M, Griesel HA, Mugabo P, Dippenaar R, van Wyk L.
Assessment of Vancomycin Pharmacokinetics and Dose Regimen
4. Zamoner W, Prado IRS, Balbi AL, Ponce D. Vancomycin dosing, Optimisation in Preterm Neonates. Drugs R D. 2020 Jun;20(2):105-13.
monitoring and toxicity: Critical review of the clinical practice. Clin Exp
Pharmacol Physiol. 2019 Apr;46(4):292-301. 19. Sethi SK, Krishnappa V, Nangethu N, Nemer P, Frazee LA, Raina R.
5. Liu SP, Xiao J, Liu YL, Wu YE, Qi H, Wang ZZ, et al. Systematic review Antibiotic Dosing in Sustained Low-Efficiency Dialysis in Critically Ill
Patients. Canadian Journal of Kidney Health and Disease [Internet].
of efficacy, safety and pharmacokinetics of intravenous and 2018 [cited 2024 Jan 30];5. Available online: www.ncbi.nlm.nih.gov/pmc/
intraventricular vancomycin for central nervous system infections. articles/PMC6088477/
Front Pharmacol. 2022 Nov 18;13:1056148.
20. Lewis SJ, Jang SM, Mueller BA. Vancomycin and daptomycin dosing
6. Vancomycin - an overview | ScienceDirect Topics [Internet]. [cited 2024 recommendations in patients receiving home hemodialysis using
Feb 17]. Available online: www.sciencedirect.com/topics/nursing-and- Monte Carlo simulation. BMC Nephrol. 2023 Sep 14;24(1):270.
health-professions/vancomycin
21. Vandecasteele SJ, De Vriese AS. Recent changes in vancomycin use in
7. Allawati H, Dallas L, Nair S, Palmer J, Thaikandy S, Hutchison C. A renal failure. Kidney Int. 2010 May;77(9):760-4.
Pharmacokinetic Study Comparing the Clearance of Vancomycin during
Haemodialysis Using Medium Cut-Off Membrane (Theranova) and High- 22. Pai AB, Pai MP. Vancomycin dosing in high flux hemodialysis: a limited-
Flux Membranes (Revaclear). Toxins (Basel). 2020 May 12;12(5):317. sampling algorithm. Am J Health Syst Pharm. 2004 Sep 1;61(17):1812-6.
8. De Cock PA, Desmet S, De Jaeger A, Biarent D, Dhont E, Herck I, et al. 23. Xiao Q, Zhang H, Wu X, Qu J, Qin L, Wang C. Augmented Renal
Impact of vancomycin protein binding on target attainment in critically Clearance in Severe Infections—An Important Consideration in
ill children: back to the drawing board? J Antimicrob Chemother. 2017 Vancomycin Dosing: A Narrative Review. Frontiers in Pharmacology
Mar 1;72(3):801-4. [Internet]. 2022 [cited 2024 Jan 30];13. Available online: www.
9. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of frontiersin.org/articles/10.3389/fphar.2022.835557
vancomycin. Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S35-9. 24. Morbitzer KA, Rhoney DH, Dehne KA, Jordan JD. Enhanced renal
clearance and impact on vancomycin pharmacokinetic parameters in
10. Westra N, Proost JH, Franssen CFM, Wilms EB, van Buren M, Touw patients with hemorrhagic stroke. J Intensive Care. 2019 Nov 21;7:51.
DJ. Vancomycin pharmacokinetic model development in patients
on intermittent online hemodiafiltration. PLoS One. 2019 May 25. Cousin L, Berre ML, Launay-Vacher V, Izzedine H, Deray G. Dosing
14;14(5):e0216801. guidelines for fluconazole in patients with renal failure. Nephrol Dial
Transplant. 2003 Nov;18(11):2227-31.
11. Beal SL, Sheiner LB. NONMEM users guides. NONMEM Project Group,
San Francisco, University of California; 1998.
12. Yukawa E. Population-based investigations of drug relative clearance Konflikt interesa: Nema
using nonlinear mixed-effect modelling from information generated
during the routine clinical care of patients. J Clin Pharm Ther. 1999 Primljeno: 20. 02. 2024.
Apr;24(2):103-13.
Prihvaćeno: 17. 03. 2024.
13. Mason NA, Neudeck BL, Welage LS, Patel JA, Swartz RD. Comparison Onlajn: 01. 06. 2024.
of 3 vancomycin dosage regimens during hemodialysis with cellulose
triacetate dialyzers: post-dialysis versus intradialytic administration.
Clin Nephrol. 2003 Aug;60(2):96-104.

12 DOI: 10.5937/Galmed2410006R